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Abstract
Background: Elucidating the genetic basis of human diseases is a central goal of genetics and molecular biology.
While traditional linkage analysis and modern high-throughput techniques often provide long lists of tens or
hundreds of disease gene candidates, the identification of disease genes among the candidates remains time-
consuming and expensive. Efficient computational methods are therefore needed to prioritize genes within the list
of candidates, by exploiting the wealth of information available about the genes in various databases.
Results: We propose ProDiGe, a novel algorithm for Prioritization of Disease Genes. ProDiGe implements a novel
machine learning strategy based on learning from positive and unlabeled examples, which allows to integrate
various sources of information about the genes, to share information about known disease genes across diseases,
and to perform genome-wide searches for new disease genes. Experiments on real data show that ProDiGe
outperforms state-of-the-art methods for the prioritization of genes in human diseases.
Conclusions: ProDiGe implements a new machine learning paradigm for gene prioritization, which could help the
identification of new disease genes. It is freely available at http://cbio.ensmp.fr/prodige.
Background
During the last decades, considerable efforts have been
made to elucidate the genetic basis of rare and common
human diseases. The discovery of so-called disease
genes, whose disruption causes congenital or acquired
disease, is indeed important both towards diagnosis and
towards new therapies, through the elucidation of the
biological bases of diseases. Traditional approaches to
discover disease genes first identify chromosomal
regions likely to contain the gene of interest, e.g., by
linkage analysis or study of chromosomal aberrations in
DNA samples from large case-control populations. The
regions identified, however, often contain tens to hun-
dreds of candidate genes. Finding the causal gene(s)
among these candidates is then an expensive and time-
consuming process, which requires extensive laboratory
experiments. Progresses in sequencing, microarray or
proteomics technologies have also facilitated the
discovery of genes whose structure or activity are modi-
fied in disease samples, on a full genome scale. How-
ever, again, these approaches routinely identify long lists
of candidate disease genes among which only one or a
few are truly the causative agents of the disease process,
and further biological investigations are required to
identify them. In both cases, it is therefore important to
select the most promising genes to be further studied
among the candidates, i.e., to prioritize them from the
most likely to be a disease gene to the less likely.
Gene prioritization is typically based on prior informa-
tion we have about the genes, e.g., their biological func-
tions, patterns of expression in different conditions, or
interactions with other genes, and follows a “guilt-by-
association” strategy: the most promising candidates
genes are those which share similarity with the disease
of interest, or with other genes known to be associated
to the disease. The availability of complete genome
sequences and the wealth of large-scale biological data
sets now provide an unprecedented opportunity to
speed up the gene hunting process [1]. Integrating a
variety of heterogeneous information stored in various
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ranking of hundreds of candidate genes is, however, a
difficult task for human experts. Unsurprisingly many
computational approaches have been proposed to per-
form this task automatically via statistical and data
mining approaches. While some previous works attempt
to identify promising candidate genes without prior
knowledge of any other disease gene, e.g., by matching
the functional annotations of candidate genes to the dis-
ease or phenotype under investigation [2-4], many suc-
cessful approaches assume that some disease genes are
already known and try to detect candidate genes which
share similarities with known disease genes for the phe-
notype under investigation [5-10] or for related pheno-
types [5,9,11-14]. These methods vary in the algorithm
they implement and in the data they use to perform
gene prioritization. For example, Endeavour and related
work [6,7,10] use state-of-the-art machine learning tech-
niques to integrate heterogeneous information and rank
the candidate genes by decreasing similarity to known
disease genes, while PRINCE [14] uses label propagation
over a protein-protein interaction (PPI) network and is
able to borrow information from known disease genes
of related diseases to find new disease genes. We refer
the reader to [15] for a recent review of gene prioritiza-
tion tools available on the web.
Here we propose ProDiGe, a new method for prioriti-
zation of disease genes based on the guilt-by-association
concept. ProDiGe assumes that a set of gene-disease
associations is already known to infer new ones, and
brings three main novelties compared to existing meth-
ods. First, ProDiGe implements a novel machine learn-
ing paradigm to score candidate genes. While existing
methods like those of [6,7,10] score independently the
different candidate genes in terms of similarity to
known disease genes, ProDiGe exploits the relative simi-
larity of both known and candidate disease genes to
jointly score and rank all candidates. This is done by
formulating the disease gene prioritization problem as
an instance of the problem known as learning from posi-
tive and unlabeled examples (PU learning) in the
machine learning community, which is known to be a
powerful paradigm when a set of candidates has to be
ranked in terms of similarity to a set of positive data
[16-18]. Second, in order to rank candidate genes for a
disease of interest, ProDiGe borrows information not
only from genes known to be associated to the disease,
but also from genes known to play a role in diseases or
phenotypes related to the disease of interest. This again
differs from [6,7,10] which treat diseases independently
from each other. It allows us, in particular, to rank
genes even for orphan diseases, with no known gene, by
relying only on known disease genes of related diseases.
In the machine learning jargon, we implement a multi-
task strategy to share information between different dis-
eases [19-21], and weight the sharing of information by
the phenotypic similarity of diseases. Third, ProDiGe
performs heterogeneous data integration to combine a
variety of information aboutt h eg e n e si nt h es c o r i n g
function, including sequence features, expression levels
in different conditions, PPI interactions or presence in
the scientific literature. We use the powerful framework
of kernel methods for data integration [22-24], akin to
the work of [6,7,10]. This differs from approaches like
that of [14], which are limited to scoring over a gene or
protein network.
We test ProDiGe on real data extracted from the
OMIM database [25]. It is able to rank the correct dis-
ease gene in the top 5% of the candidate genes for 69%
of the diseases with at least one other known causal
gene, and for 67% of the diseases when no other disease
genes is known, outperforming state-of-the-art methods
like Endeavour and PRINCE.
Results
Gene prioritization without sharing of information across
diseases
We first assess the ability of ProDiGe to retrieve new
disease genes for diseases with already a few known dis-
ease genes, without sharing information across different
diseases. As a gold standard we extracted all known dis-
ease-gene associations from the OMIM database [25],
and we borrowed from [7] nine sources of information
about the genes, including expression profiles in various
experiments, functional annotations, known protein-pro-
tein interactions (PPI), transcriptional motifs, protein
domain activity and literature data. Each source of infor-
mation was encoded in a kernel functions, which
assesses pairwise similarities between each pair of genes
according to each source of information. We compare
two ways to perform data integration: first by simply
averaging the nine kernel functions, and second by let-
ting ProDiGe optimize itself the relative contribution of
each source of information when the model is estimated,
through a multiple kernel learning (MKL) approach. We
compare both variants with the best model of [10],
namely, the MKL1Class model which differs from Pro-
DiGe in this case only in the machine learning paradigm
implemented: while ProDiGe learns a model from posi-
tive and unlabeled examples, MKL1class learns it only
from positive examples. Since [10] showed that
MKL1Class outperforms the original Endeavour algo-
rithm based on fusion of rankings [6] and may replace it
in the future, we take the performance of MKL1Class as
an optimistic surrogate of Endeavour’s performance. We
tested these three algorithm in a leave-one-out cross-
validation (LOOCV) setting. In short, for each disease,
each known disease gene was removed in turn, a model
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positive examples, and all 19540 genes in our database
were ranked; we then recorded the rank of the positive
gene that was removed in this list. We focused on the
285 diseases in our dataset having at least 2 known dis-
ease genes, because all three methods require at least
one known disease gene for training, and for the pur-
pose of LOOCV we need in addition one known disease
gene removed from the training set.
Figure 1 presents the cumulative distribution function
(CDF) of the rank of the left-out positive gene, i.e., the
number of genes that were ranked in the top k genes of
the list as a function of k, for each method. Note that
the rank is always between 1 (best prediction) and
19540 - |P|, where |P| is the number of genes known to
be associated to the disease of interest. The right panel
zooms on the beginning of this curve which corresponds
to the distribution of small values of the rank. We see
clearly that both ProDiGe variants outperform
MKL1class in the sense that they consistently recover
the hidden positive gene at a better rank in the list. A
Wilcoxon signed rank test confirms these visual conclu-
sions at 5% level with P-values 6.1e
-29 and 8.8e
-28,
respectively, for the average and MKL variants of Pro-
DiGe. This illustrates the benefits of formulating the
gene ranking problem as a PU learning problem, and
not as a 1-class learning one, since apart from this for-
mulation both MKL1Class and ProDiGe1 use very simi-
lar learning engines, based on SVM and MKL.
Both ProDiGe1 variants recover roughly one third of
correct gene-disease associations in the top 20 genes
among almost 19540, i.e., in the top 0.1%. However, we
found no significant difference between the mean and
MKL variants of ProDiGe in this setting (P-value =
0.619). This means that in this case, assigning equal
weights to all data sources works as well as trying to
optimize these weights by MKL. Supported by this result
and by the fact that MKL is much more time-consum-
ing than a SVM with the mean kernel, we decided to
restrict our experiments to the mean kernel in the fol-
lowing experiments.
Gene prioritization with information sharing across
diseases
In a second run of experiments, we assess the performance
of ProDiGe when it is allowed to share informations across
diseases. We tested three variants of ProDiGe, as explained
in Material and Methods: ProDiGe2, which uniformly
shares information across all diseases without using parti-
cular informations about the diseases, ProDiGe3, which
weights the sharing of informations across diseases by a
phenotypic similarity between the diseases, and ProDiGe4,
a variant of ProDiGe3 which additionally controls the
sharing of information between diseases that would have
very similar phenotypic description but which remain dif-
ferent diseases. All variants are based on the same metho-
dological backbone, namely, the use of a multitask
learning strategy, and only differ in a function used to con-
trol the sharing of information. We limit ourselves to the
1873 diseases in the disease-gene association dataset
which were also in the phenotypic similarity matrix that
we used. This corresponds to a total of 2544 associations
between these diseases and 1698 genes. We compare these
variants to PRINCE [14], a method recently proposed to
rank genes by sharing information across diseases through
label propagation on a PPI network.
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Figure 1 Cumulative distribution function of the rank for local methods, in the LOOCV experiment. ProDiGe1-Mean and ProDiGe1-MKL
refer to the ProDiGe1 variant combined with the mean kernel or the MKL strategy to fuse heterogeneous gene information. Panel (A) Global
curve, Panel (B) Zoom on the beginning of the curve.
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Page 3 of 15Figure 2 shows the CDF curves for the four methods.
Comparing areas under the global curve, i.e., the average
rank of the left-out disease gene in LOOCV, the four
methods can be ranked in the following order: Pro-
DiGe4 (1682) > ProDiGe3 (1817) > ProDiGe2 (2246) >
PRINCE (3065). The fact that ProDiGe3 and ProDiGe4
outperform ProDiGe2 confirms the benefits of exploit-
ing prior knowledge we have about the disease pheno-
types to weight the sharing of information across
diseases, instead of following a generic strategy for mul-
titask learning. The fact that ProDiGe4 outperforms
ProDiGe3 is not surprising and illustrates the fact that
the diseases are not fully characterized by the phenoty-
pic description we use. Zooming to the beginning of the
curves (right picture), we see that the relative order
between the methods is conserved except for PRINCE
which outperforms ProDiGe2 in that case. In fact, Pro-
D i G e 2h a sav e r yl o wp e r f o r m a n c ec o m p a r e dt oa l l
other methods for low ranks, confirming that the gen-
eric multitask strategy should not be pursued in practice
if phenotypic information is available.
The fact that ProDiGe3 and ProDiGe4 outperform
PRINCE for all rank values confirm the competitive-
ness of our approach. On the other hand, the compari-
son with PRINCE is not completely fair since ProDiGe
exploits a variety of data sources about the genes,
w h i l eP R I N C Eo n l yu s e saP P In e t w o r k .I no r d e rt o
clarify whether the improvement of ProDiGe over
PRINCE is due to a larger amount of data used, to the
learning algorithm, or to both, we ran ProDiGe3 with
only the kernel derived from the PPI network which
we call ProDiGe-PPI in Figure 2. In that case, both
ProDiGe and PRINCE use exactly the same
information to rank genes. We see on the left picture
that this variant is overall comparable to PRINCE (no
significant difference between PRINCE and ProDiGe-
PPI with a Wilcoxon paired signed rank test), confirm-
ing that the main benefit of ProDiGe over PRINCE
comes from data integration. Interestingly though, at
the beginning of the curve (right picture), ProDiGe-
PPI is far above PRINCE, and even behaves compar-
ably to the best method ProDiGe4. Since ProDiGe-PPI
and PRINCE use exactly the same input data, this
means that the better performance of ProDiGe-PPI for
low ranks comes from the learning method based on
PU learning with SVM, as opposed to label propaga-
tion over the PPI network.
To better visualize the differences between the dif-
ferent variants of ProDiGe, the scatter plots in Figure
3 compare directly the ranks obtained by the different
variants for each of the 2544 left-out associations.
Note that smaller ranks are better than large ones,
since the goal is to be ranked as close as possible to
the top of the list. On the left panel, we compare Pro-
DiGe3 to ProDiGe4. We see that many points are
below the diagonal, meaning that adding a Dirac ker-
nel to the Phenotype kernel (ProDiGe4) generally
improves the performance as compared to using a
Phenotype kernel (ProDiGe3) alone. On the right
panel, the ProDiGe2 is compared to the ProDiGe3.
We see that the points are more concentrated above
the diagonal, but with large variability on both sides
of the diagonal. This indicates a clear advantage in
favor of the Phenotype kernel compared to the gen-
eric Multitask kernel, although the differences are
quite fluctuant.
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Figure 2 Cumulative distribution function of ranks in the LOOCV experiments, for global approaches. ProDiGe2, 3, 4 refer to the three
variants of ProDiGe which share information, while ProDiGe-PPI refers to ProDiGe3 trained only the PPI network data. Panel (A) Global curve.
Panel (B) Zoom on the beginning of the curve.
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Page 4 of 15Is sharing information across diseases beneficial?
In order to check whether sharing information across
diseases is beneficial, we restrict ourselves to diseases
with phenotypic informations and with at least two
known associated genes in the OMIM database. This
way, we are able to share information across diseases
and, at the same time, to run methods that do not share
information because we ensure that there is at least one
training gene in the LOOCV procedure. This leaves us
with 265 diseases, corresponding to 936 associations.
Figure 4 shows the CDF curves of the rank for the
various methods on these data, including the two
methods MKL1class and ProDiGe1 (with the mean ker-
nel for data integration), which do not share information
across diseases, and ProDiGe 2, 3, 4 and PRINCE, which
do share information. Interestingly, we observe different
retrieval behaviors on these curves, depending on the
part of the curve we are interested in. On the one hand,
if we look at the curves globally, ProDiGe 4 and 3 per-
form very well, having high area under the CDF curve, i.
e., a low average rank (respectively 1529 and 1770).
PRINCE and MKL1class have the worse average ranks
(respectively 3220 and 3351). A systematic test of differ-
ences between the methods, using a Wilcoxon paired
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Figure 3 Comparison of rank measures between different variants of ProDiGe. Each point represent a disease-gene association. We plot
the rank they obtain from the different methods when they are left out in the LOOCV procedure. Small ranks are therefore better than large
ranks.
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Figure 4 Cumulative distribution function of ranks for local and multitask approaches. (A) Global curve. (B) Zoom on the beginning of the
curve.
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Page 5 of 15signed rank test over the ranks for each pair of methods,
is summarized in Figure 5. In this picture, an arrow
indicates that a method is significantly better than
another at level 5%. This confirms that ProDiGe 4 is the
best method, significantly better than all other ones
except ProDiGe 1. Three variants of ProDiGe are signifi-
cantly better than PRINCE and MKL1Class.
On the other hand, in the context of gene prioritiza-
tion, it is useful to focus on the beginning of the curve
and not on the full CDF curves. Indeed, only the top of
the list is likely to deserve any serious biological investi-
gation. Therefore we present a zoom of the CDF curve
in panel (B) of Figure 4. We see there that the local
methods ProDiGe1 and MKL1class present a sharper
increase at the beginning of the curve than the global
methods, meaning that they yield more often truly dis-
ease genes near the very top of the list than other meth-
ods. Additionally, we observe that ProDiGe1 is in fact
t h eb e s tm e t h o dw h e nw ef o c u so nt h ep r o p o r t i o no f
disease genes correctly identified in up to the top 350
among 19540, i.e., in up to the top 1.8% of the list.
These results are further confirmed by the quantitative
values in Table 1, which show the recall (i.e., CDF
value) as a function of the rank. ProDiGe 1, which does
not share information across diseases, is the best when
we only focus at the very top of the list (up to the top
1.8%), while ProDiGe 4, which shares information, is
then the best method when we go deeper in the list.
At this point it is interesting to question what position
in the list we are interested in. In classical applications
where we start from a short list of, say, 100 candidates,
then being in the top 5% of the list means that the cor-
rect gene is ranked in the top 5 among the 100 candi-
dates, while the top 1% corresponds to the first of the
list (see the last 3 columns of Table 1). If we only focus
on the first gene of a short list of 100 candidates, then
ProDiGe1 is the best method, with almost half of the
genes (49.2%) found in the first position, followed by
ProDiGe4 (43.4%) and MKL1class (41.1%). As soon as
we accept to look further than the first place only, Pro-
DiGe 4 is the best method, with 68.9% of disease genes
in the top 5 of a list of 100 candidates, for example. On
the other hand, if we consider a scenario where we start
from no short list of candidates, and directly wish to
predict disease genes among the 19540 human genes,
then only the few top genes in the list are interesting
(see the first 2 columns of Table 1). In that case, the
methods that do not share information are clearly pre-
ferable, with 27.8% (resp 25.3%) of genes correctly found
in the top 10 among 19540 for ProDiGe 1 (resp.
MKL1class).
In summary, sharing information is not beneficial if
we are interested only in the very top of the list, typi-
cally the top 10 among 19540 candidates. This setting is
however very challenging, where even the best method
ProDiGe1 only finds 12.3% of all disease genes. As soon
as we are interested in more than the top 2% of the list,
which is a reasonable level when we start from a short
list of a few tens or hundreds of candidate genes, shar-
ing information across diseases becomes interesting. In
all cases, some variant of ProDiGe outperforms existing
methods. In particular ProDiGe4, which shares informa-
tion using phenotypic information across diseases while
keeping different diseases distinct, is the best way to
share information.
Predicting causal genes for orphan diseases
Finally, we investigate the capacity of the different gene
prioritization methods to identify disease genes for
Figure 5 Wilcoxon paired signed rank tests for significant rank
difference between all methods. ProDiGe1 and MKL1class are the
only local approaches, which do not share information across
diseases. The number in each ellipse is the average rank obtained
by the method in the LOOCV procedure. An arrow indicates that a
method is significantly better than another.
Table 1 Recall of different methods at different rank
levels, for diseases with at least one known disease
gene.
top 1 top 10 top 1% top 5% top 10%
MKL1class 11.5 25.3 41.1 52.8 59.9
ProDiGe1 12.3 27.8 49.2 61.9 71.2
ProDiGe2 0.1 0.7 17.8 51.2 66.9
ProDiGe3 1.9 11.4 38.6 64.0 74.2
ProDiGe4 3.1 14.6 43.4 68.9 78.4
PRINCE 1.5 6.8 37.3 57.1 65.4
The recall at rank level k is the percentage of disease genes that were
correctly ranked in the top k candidate genes in the LOOCV procedure, where
the number of candidate genes is near 19540. Top 1 and top 10 (first two
columns) correspond respectively to the recall at the first and first ten genes
among 19540, while top X% (last three columns) refer to the recall at the first
X% genes among 19540.
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Page 6 of 15orphan diseases, i.e., diseases with no known causative
gene yet. ProDiGe1 and MKL1class, which treat diseases
independently from each other and require known dis-
ease genes to find new ones, can not be used in this set-
ting. Methods that share information across diseases, i.
e., ProDiGe2, 3, 4 and PRINCE, can be tested in this
context, since they may be able to discover causative
genes for a given orphan diseases by learning from cau-
sative genes of other diseases. In fact, ProDiGe3 and
ProDiGe4 boil down to the same method in this con-
text, because the contribution of the Dirac kernel in (6)
vanishes when no known disease gene for a disease of
interest is available during training. We summarize
them by the acronym ProDiGe3-4 below.
To simulate this setting, we start from the 1608 dis-
eases with only one known disease gene in OMIM and
phenotypic information, resulting in 1608 disease-gene
associations involving 1182 genes. For each disease in
turn, the associated gene is removed from the training
set, a scoring function is learned from the associations
involving other diseases, and the removed causal gene is
ranked for the disease of interest. We compute the rank
of the true disease gene, and repeat this operation for
each disease in turn. Figure 6 and Table 2 show the per-
formance of the different global methods in this setting.
Interestingly, they are very similar to the results
obtained in the multitask setting (Figure 2 and Table 1),
both in relative order of the methods and in their abso-
lute performance. Overall, ProDiGe3-4 performs best,
retrieving the true causal gene in the top 10 genes of
the list 13.1% of times, and in the top 5% of candidate
genes 66.9% of times. This is only slightly worse than
the performance reached for diseases with known
disease genes (respectively 14.6% and 68.9%), highlight-
ing the promising ability of global approaches to deor-
phanize diseases.
Validation on selected diseases
To further validate ProDiGe, we used the whole training
set to prioritize the unlabeled genes for a few particular
diseases with ProDiGe4. We completed the training set
with a list of genes collected through the use of Ingenu-
i t yP a t h w a y sA n a l y s i s( I P A ,I n g e n u i t y
® Systems). In
Table 3, we report the results of this validation for a
first set of diseases having a training set of positive
genes of reasonable size (more than 11 genes). These
diseases are in the same order: prostate cancer [MIM
176807], colorectal cancer [MIM 114500], diabetes mel-
litus [MIM 125853], Alzheimer [MIM 104300], gastric
cancer [MIM 137215], leukemia acute myeloid [MIM
601626], breast cancer [MIM 114480], schizophrenia
[MIM 181500]. The columns report successively the dis-
ease name, the MIM id of the disease, the size of the
training set, the size of the intersection between the
training set and the Ingenuity list, the estimated preci-
sion and recall of the top 100 genes in the prioritized
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Figure 6 Cumulative distribution function of ranks for prioritization of causal genes for orphan diseases. Panel (A) Global curve. Panel
(B) Zoom on the beginning of the curve.
Table 2 Recall of different methods at different rank
levels, for orphan diseases
top 1 top 10 top 1% top 5% top 10%
ProDiGe2 0.1 1.4 16.8 50.4 68.1
ProDiGe3-4 1.9 13.1 42.7 66.9 76.1
PRINCE 0.5 4.8 36.9 52.9 60.6
In this case, since the disease has no known causal genes, only the causal
genes of other diseases intervene in the learning, meaning that ProDiGe3 and
4 are equivalent approaches.
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Page 7 of 15list and the p-value of a hypergeometric test. The preci-
sion is estimated as the fraction of the top 100 genes
that are also in the IPA list while recall is the fraction of
the IPA list that intersects the top 100 genes of the
prioritized list. Of course, the true precision value is
unknown and the value we report underestimates the
true value. The hypergeometric test allows to test for
t h ee n r i c h m e n to ft h et o p1 0 0g e n e so fo u rp r i o r i t i z e d
list in genes known to be associated to the disease,
which were not in the training set (namely genes pre-
v i o u s l ye x t r a c t e df r o mI P A ) .W ec a ns e et h a tp r e c i s i o n
is good, except for schizophrenia, gastric cancer and leu-
kemia. Recall on the other hand is not very high but the
values are limited by the large size of IPA lists. All tests
are significant at 5% level.
We then did the same for 8 diseases with only 2
known genes in our training set: glaucoma [MIM
606657], Creutzfeld-Jacob [MIM 123400], hyperpar-
athyroidism [MIM 145000], psoriasis [MIM 177900],
glioblastoma [MIM 137800], cystic fibrosis [MIM
219700], pancreatic carcinoma [MIM 260350], thalasse-
mia [MIM 604131]. Results are given in Table 4. As
expected, precision is much smaller for these diseases.
However, we see that sharing information across dis-
eases still allows to retrieve new disease genes for dis-
eases where the training set is very small.
Further validation include Table 5 which reports the
top ten genes of the prioritized list for prostate cancer,
colorectal cancer, diabetes mellitus, Alzheimer, gastric
cancer, leukemia acute myeloid, breast cancer, schizo-
phrenia. These lists were analyzed with GeneValoriza-
tion [26], a text-mining tool for automatic bibliography
search.
Discussion
A particularity of ProDiGe is the possibility to encode
prior knowledge on disease relatedness through the dis-
ease kernel. While a Dirac kernel prevents sharing of
information across diseases, we tested different variants
to share information including a generic multitask ker-
nel and kernels taking into account the phenotypic simi-
larity between diseases. We demonstrated the relevance
of using the phenotypic similarity, compared to the gen-
eric multitask kernel, and have enhanced it by the addi-
tion of a Dirac kernel. Given the influence of the disease
kernel on the final performance of the method, we
believe that there is still much room for improvement in
the design of the prior, using the general ProDiGe fra-
mework. We note in particular that if other descriptors
were available for phenotypes, one could also integrate
these data and the prior they induce on task relatedness
in the disease kernel.
A important question in practice is to choose between
the two variants. We have seen that ProDiGe1 has
higher recall in the top 1 or 2% of the list, while Pro-
DiGe4 is better after. Hence a first criterion to chose
among them is the rank level that we are ready to inves-
tigate. In addition, one could think that ProDiGe1,
Table 3 Prioritization with ProDiGe4 for 8 diseases with a large training set of known genes
Disease name MIM Id Training set Training ∩ IPA Precision (%) Recall (%) P-value
Prostate cancer 176807 12 12 41 7.5 5.3e
-40
Colorectal cancer 114500 17 17 51 5.7 7.3e
-44
Diabetes mellitus 125853 26 22 21 1.4 2.1e
-06
Alzheimer 104300 11 10 23 2.3 3.8e
-11
Gastric cancer 137215 12 12 16 7.1 9.3e
-16
Leukemia acute myeloid 601626 17 16 13 10.0 2.8e
-15
Breast cancer 114480 19 16 33 3.7 6.4e
-22
Schizophrenia 181500 17 11 6 3.2 4.5e
-05
The results were validated by comparing our top 100 genes with a list of genes related to the disease, extracted from Ingenuity database.
Table 4 Prioritization with ProDiGe4 for 8 diseases with only 2 known genes
Disease name MIM Id Training ∩ IPA Precision (%) Recall (%) P-value
Glaucoma 606657 2 8 12.5 2.0e
-11
Creutzfeld-Jacob 123400 2 2 40.0 1.3e
-06
Hyperparathyroidism 145000 2 3 18.7 1.1e
-06
Psoriasis 177900 2 4 6.0 1.8e
-05
Glioblastoma 137800 2 16 10.7 8.4e
-19
Cystic fibrosis 219700 2 5 10.6 9.3e
-08
Pancreatic carcinoma 260350 1 8 9.6 2.3e
-10
Thalassemia 604131 0 2 25.0 2.6e
-06
The results were validated by comparing our top 100 genes with a list of genes related to the disease, extracted from Ingenuity database.
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Page 8 of 15which can not be used for orphan disease, is more gen-
erally handicapped compared to ProDiGe4 when the
number of known disease genes is small, while it is in a
better situation when many genes are already known.
Indeed, if enough causal genes are known for a given
disease, there is intuitively no need to borrow informa-
tion from other diseases, which may mislead the predic-
tion. This dependency of the relative performance of a
local and a global approach on the number of training
samples has previously been observed in other contexts
[21] where a global approach was shown to bring tangi-
ble improvements over a local one when the number of
positive examples was low. We have however checked
for the presence of such an effect, and found that it
could not be brought to light, as illustrated in Figure 7
which plots the mean and standard deviation of the
rank of the left-out gene in LOOCV as a function of the
number of known genes of the disease during training.
We observe no trend indicating that the performance
increases with the number of training genes, and no dif-
ferent behaviour between the local and multitask
approaches, as long as at least one disease gene is
known. This surprising finding, which is coherent with
the observation that there is no big difference in perfor-
mance for orphan and non-orphan diseases, suggests
that the number of known disease genes in not a rele-
vant criterion to choose between the local and multitask
version of ProDiGe. Instead, we suggest in practice to
use the local version ProDiGe 1 if we are interested only
in genes ranked in the very top of the candidate gene
lists (below the top 1%), and ProDiGe 4 as soon as we
can afford going deeper in the list.
Conclusions
We have introduced ProDiGe, a new set of methods for
disease gene prioritization. ProDiGe integrates heteroge-
neous information about the genes in a unified PU
learning strategy, and is able to share information across
different diseases if wanted. We have proposed in parti-
cular two flavours for disease gene ranking: ProDiGe1,
which learns new causal genes for each disease sepa-
rately, based on already known causal genes for each
disease, and ProDiGe4, which additionally transfers
information about known disease genes across different
diseases, weighting information sharing by disease phe-
notypic similarity. We have demonstrated the efficiency
of both variants on real data from the OMIM database
w h e r et h e yo u t p e r f o r mE n d e a v o u ra n dP R I N C E ,t w o
state-of-the-art gene prioritization methods.
Table 5 The top ten genes for 8 diseases with a
reasonable training set
Prostate cancer Gastric cancer
CDKN2A(1029) 210 1 EGFR(1956) 853 1
AKT1(207) 1058 1 AKT1(207) 272 0
IGF1R(3480) 152 1 EXT1(2131) 4 0
MSX1(4487) 5 0 FAS(355) 180 0
PAX3(5077) 2 0 LRP5(4041) 8 0
CCND1(595) 372 1 MSX1(4487) 3 0
BRAF(673) 22 1 CCND1(595) 250 1
TP53(7157) 1378 1 BRAF(673) 32 1
WFS1(7466) 0 0 TP53(7157) 1593 1
WT1(7490) 37 1 WFS1(7466) 0 0
Colorectal cancer Leukemia acute myeloid
CDKN2A(1029) 415 1 AKT1(207) 233 0
EXT1(2131) 14 0 FAS(355) 136 0
IGF1R(3480) 86 1 KRAS(3845) 457 1
SMAD4(4089) 211 1 LYN(4067) 26 0
MLH1(4292) 4064 1 MYC(4609) 381 0
PDGFRA(5156) 19 1 RAF1(5894) 30 1
PDGFRB(5159) 45 1 STAT3(6774) 95 0
BRAF(673) 430 1 STK11(6794) 2 0
WFS1(7466) 0 1 BTK(695) 6 0
WT1(7490) 15 0 TP53(7157) 474 1
Diabetes mellitus Breast cancer
COL1A1(1277) 4 0 CDKN2A(1029) 572 1
COL2A1(1280) 6 0 COL2A1(1280) 9 0
CYP3A5(1577) 5 0 COL3A1(1281) 1 0
EXT1(2131) 20 1 EXT1(2131) 22 0
GHR(2690) 49 0 LRP5(4041) 51 0
ABCC6(368) 43 0 MSX1(4487) 10 0
LEP(3952) 754 1 PAX3(5077) 6 0
LRP5(4041) 58 0 PITX2(5308) 310 1
CACNA1S(779) 4 0 BRAF(673) 37 1
ADIPOQ(9370) 1635 1 WFS1(7466) 4 0
Alzheimer Schizophrenia
COL2A1(1280) 0 0 COL1A1(1277) 0 0
CYP1B1(1545) 0 0 COL2A1(1280) 0 0
EXT1(2131) 4 1 ATN1(1822) 40 0
ALDH3A2(224) 4 0 EXT1(2131) 20 0
APOE(348) 4143 1 FGFR3(2261) 78 0
ABCC6(368) 10 0 GJB1(2705) 0 0
LRP5(4041) 3 0 ABCC6(368) 7 0
MAOA(4128) 5 1 LRP5(4041) 4 0
PSEN2(5664) 635 1 PARK2(5071) 1 0
WFS1(7466) 1 0 WFS1(7466) 5 0
These diseases are in order: prostate cancer [MIM 176807], colorectal cancer
[MIM 114500], diabetes mellitus [MIM 125853], Alzheimer [MIM 104300],
gastric cancer [MIM 137215], leukemia acute myeloid [MIM 601626], breast
cancer [MIM 114480], schizophrenia [MIM 181500]. Using GeneValorization, we
counted the number of publication hits in NCBI which are found to be
relevant to a query disease and a query gene. At last, the third column
indicates whether the gene belongs to the list extracted from the Ingenuity
Pathways Analysis tool.
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view on this long-studied gene prioritization problem is
novel. Classical one-class approaches which learn a scor-
ing function to rank candidate genes using known dis-
ease genes only are prone to over-fitting in large
dimensions when the training set if small, which results
in poor performance. We observed that our PU learning
strategy, augmented by a multitask point of view to
share information across diseases, was useful to obtain
better results in the disease gene identification task. In
fact, learning from positive and unlabeled examples is a
common situation in bioinformatics, and PU learning
methods combined or not with multitask kernels have a
good potential for solving many problems such as path-
way completion, prioritization of cancer patients with a
higher risk of relapse, or prediction of protein-protein
or protein-ligand interactions.
Methods
The gene prioritization problem
Let us first formally define the disease gene prioritiza-
tion problem we aim to solve. We start from a list of N
human genes G = {G1,...,GN}, which typically can be
the full human genome or a subset of interest where
disease genes are suspected. A multitude of data sources
to characterize these genes are given, including for
instance expression profiles, functional annotation,
sequence properties, regulatory information, interac-
tions, literature data, etc... We assume that for each data
source, each gene G ∈ G is represented by a finite- or
infinite-dimensional vector F(G), which defines an inner
product K(G,G’)=F(G)
⊤F(G’) between any two genes
G and G’. K is called a kernel in the machine learning
community [28]. Intuitively, K(G,G’)m a yb et h o u g h to f
as a measure of similarity between genes G and G’
according to the representation defined by F. Since sev-
eral representations are available, we assume that L fea-
ture vector mappings F1,...,FL are available,
corresponding to L kernels for genes K1,K2,...,KL. Finally,
we suppose given a collection of M disorders or disease
phenotypes D = {D1,...,DM}. For each disorder Di,t h e
learner is given a set of genes Pi ⊂ G , which contains
known causal genes for this phenotype, and a set of can-
didate genes Ui ⊂ G where we want to find new disease
genes for Di.T y p i c a l l yUi can be the complement set of
Pi in G if no further information about the disease is
available, or could be a smaller subset if a short list of
candidate genes is given for the disease Di. For each dis-
ease Di, our goal is to retrieve more causal genes for Di
in Ui. In practice, we aim at ranking the elements of Ui
from the most likely disease gene to the less likely, and
we assess the quality of a ranking by its capacity to rank
the true disease genes at or near the top of the list.
Gene prioritization for a single disease and a single data
source
Let us first describe our gene prioritization approach
ProDiGe for a single disease (M =1 )a n das i n g l ed a t a
source (L = 1). In that case, we are given a single list of
disease genes P ⊂ G , and must rank the candidate
genes in U ⊂ G using the kernel K.A se x p l a i n e di nt h e
Introduction, most existing approaches define a scoring
function s : U ® ℝ, using only positive examples in P,
to quantify how similar a gene G in U is to the known
disease genes in P. Here we propose to learn the scoring
function s(.) both from P and U, by formulating the pro-
blem as an instance of PU learning.
Intuitively, the motivation behind PU learning is to
exploit the information provided by the distribution of
unlabeled examples to improve the scoring function, as
illustrated in Figure 8. Here we initially have a set of
positive examples (genes known to be related to a given
disease for instance) which are represented on the graph
by blue crosses, and we want to retrieve more of them.
Traditional approaches which define a scoring function
from P usually try to estimate the support of the
Figure 7 Effect of the number of related genes on the performance. This figure shows the performance of each method, measured as the
mean rank of the positive genes, as a function of the number of known causal genes for the disease considered.
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genes”, which could be in that case delimited by the
dashed line. Now suppose that we additionally observe a
set of unlabeled examples (candidate genes), represented
by U letters. Green Us are positive unlabeled and red
ones are negative unlabeled, but this information is not
available. Then, we can have the feeling that the bound-
ary should rather be set in the low density area as repre-
sented by the solid line, which better captures reality
than the dashed line. Consequently, using the distribu-
tion of U in addition to the positive examples can help
us better characterize the area of positive examples.
This is particularly true in high dimension with few
examples, where density estimation from a few positive
examples is known to be very challenging.
In practice, a simple and efficient strategy to solve a
PU learning problem is to assign negative labels to ele-
ments in U, and train a binary classifier to discriminate
P from U, allowing errors in the training labels. Assum-
ing that the binary classifier assigns a score to each
point during training (which is the case of, e.g., logistic
regression or SVM), the score of an element in U is
then just the scored assigned to it by the classifier after
training. This approach is easy to implement and it has
been shown that building a classifier that discriminates
the positive from the unlabeled set is a good proxy to
building a classifier that discriminates the positive from
the negative set. When the binary classifier used is a
SVM, this approach leads to the biased SVM of [16],
which was recently combined with bagging to reach fas-
ter training time and equal performance [18]. In prac-
tice, the biased SVM over-weights positive examples
during training to account for the fact that they repre-
sent high-confidence examples whereas the “negative”
examples are known to contain false negatives, namely,
t h o s ew eh o p et od i s c o v e r .H e r ew eu s et h ev a r i a n to f
[18], which adds a bootstrap procedure to biased SVM.
The additional bagging-like feature takes advantage of
the contaminated nature of the unlabeled set, allowing
to reach the same performances while increasing both
speed and scalability to large datasets. The algorithm
takes as input a positive and an unlabeled set of exam-
ples, and a parameter B specifying the number of boot-
strap iterations. It discriminates the positive set from
random subsamples of the unlabeled set and aggregates
the successive classifiers into a single one (bootstrap
aggregating). The output is a score function s such that
for any example G, s(G) reflects our confidence that G
is a positive example. We then rank elements in U by
decreasing score. For more details on the method, we
refer the reader to [18]. In practice, we implement the
SVM with the libsvm implementation [29]. After obser-
ving in preliminary experiments that the regularization
parameter C of the SVM did not dramatically affect the
final performance, we set it constant to the default value
C = 1 for all results shown below. The number of boot-
strap iterations was set to B = 30.
Gene prioritization for a single disease and multiple data
sources
When several data sources are available to characterize
genes, e.g., gene expression profiles and sequence fea-
tures, we extend our PU learning method to learn
simultaneously from multiple heterogeneous sources of
data through kernel data fusion [24]. Formally, each
data source is encoded in a kernel function, resulting in
L ≥ 1 kernels K1,..., KL. We investigate the following two
strategies to fuse the L data sources.
First, we simply define a new kernel which integrates
the information contained in all kernels as the mean of
the L kernels, i.e., we define:
Kint =
1
L
L 
i=1
Ki. (1)
In other words, the kernel similarity Kint(G,G’)
between two genes is defined as the mean similarity
between the two genes over the different data sources.
This simple approach is widely used and often leads to
very good performance with SVM to learn classification
models from heterogeneous information [22,30,31]. In
our setting, we simply use the integrated kernel (1) each
Figure 8 An intuitive example of how the unlabeled examples
could be helpful. This figure illustrates the potential benefits of
using unlabeled examples when the ranking function is run. When
only positive examples are used (blue crosses), a machine learning
method may define a region surrounding them as the region of
positive examples (in dotted lines). Using in addition unlabeled
examples may suggest a different region, such as a frontier
between positive and negative examples in a region with few
points.
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described in the previous section, to estimate a prioriti-
zation score from multiple data sources.
Alternatively, we test a method for multiple kernel
learning (MKL) proposed by [24,32], which amounts to
building a weighted convex combination of kernels of
the form
KMKL =
1
L
L 
i=1
βiKi, (2)
where the non-negative weights bi are automatically
optimized during the learning phase of a SVM. By
weighting differently the various information sources,
the MKL formulation can potentially discard irrelevant
sources or give more importance to gene descriptors
with more predictive power. Again, combining MKL
with our PU learning strategy described in the previous
s e c t i o ni ss t r a i g h t f o r w a r d :w es i m p l yu s et h eM K Lf o r -
mulation of SVM instead of the classical SVM each
time a SVM is trained.
Gene prioritization for multiple diseases and multiple
data sources
When multiple diseases are considered, a first option is
to treat the diseases independently from each other, and
apply the gene prioritization strategy presented in the
two previous sections to each disease in turn. However,
it is known that disease genes share some common
characteristics [27,33,34], and that similar diseases are
often caused by similar genes [5,9,11-14]. This suggests
that, instead of treating each disease separately, it may
be beneficial to consider them jointly and share infor-
mation of known disease genes across diseases. By
mutualizing information across diseases, one may in
particular attempt to prioritize genes for orphan dis-
eases, with no known causal gene. This is an important
property since these diseases are obviously those for
which predictions are the most needed.
We propose to jointly solve the gene prioritization
problem for different diseases by formulating it as a
multitask learning problem, and we adapt the multitask
learning strategy of [19] to our PU learning framework.
In this setting, instead of just learning a scoring function
over individual genes G ∈ G to rank candidates for a
disease, we learn a scoring function over disease-gene
pairs of the form (D,G) ∈ D × G . In order to learn this
scoring function, instead of starting from a set of posi-
tive examples P ⊂ G made of known disease genes for a
particular disease, we start from a set of positive pairs
(Dd(i),Gg(i))i=1,...,T ⊂ D × G obtained by combining the
pairs where gene Gg(i) is known to be a disease gene for
disease Dd(i). T is then the total number of known
disease-gene pairs. Given the training set of disease-gene
pairs, we then learn a scoring function s over D × G
using our general PU learning algorithm described ear-
l i e ri nt h ec o n t e x to fas i n g l ed i s e a s e ,w h e r et h ek e r n e l
function between two disease-gene pairs (D, G) and (D’,
G’) is of the form:
Kpair((D,G),(D ,G ))
= Kdisease(D,D ) × Kgene(G,G ).
(3)
In this equation, Kgene is a kernel between genes, typi-
cally equal to one of the kernels described earlier in the
context of gene prioritization for a single disease. Kdisease
is a kernel between diseases, which allows sharing of
information across diseases, as in classical multitask
learning with kernels [19-21]. More precisely, we con-
sider the following variants for Kpair,w h i c hg i v er i s et o
various gene prioritization methods:
￿ The Dirac kernel is defined as
KDirac(D,D )=

1i fD = D ,
0o t h e r w i s e .
(4)
Plugging the Dirac kernel into (3), we see that the
pairwise kernel between two disease-gene pairs for
different diseases is 0. One can then show that there
is no sharing of information across diseases, and that
learning over pairs in this context boils down to
treating each disease independently from the others
[19-21]. This is thus our baseline strategy, which
treats each disease in turn, and does not provide a
solution for orphan diseases. We call this method
ProDiGe1 below.
￿ The multitask kernel is defined by
Kmultitask(D,D )=1+KDirac(D,D ). (5)
This kernel, which was proposed by [19], allows a
basic sharing of information across diseases. In addi-
tion to the genes known to be causal for a disease of
interest through the Dirac kernel, the addition of a
constant in (5) allows all other known disease genes
for other diseases to play the role of positive training
examples, although to a lesser extent than the dis-
ease genes for the disease of interest. Here we do
not use any specific knowledge about the different
diseases and their similarity, and simply try to cap-
ture properties that may be shared by disease genes
in general. This corresponds to a low information
prior because a disease equally exploits knowledge
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DiGe2 below.
￿ The phenotype kernel is an attempt to capture
phenotypic similarities between diseases to control
the sharing of information across diseases. Indeed,
m a n yp r e v i o u sw o r k sh a v eu s e da sp r i o rk n o w l e d g e
the fact that similar phenotypes are likely to be
caused by similar genes [5,9,11-14,35]. This suggests
that, instead of sharing information uniformly across
diseases as the multitask kernel (5) does, it may be
beneficial to do it in a more principled way. In parti-
cular, the more similar two diseases are, the more
they should share information. In practice, this is
obtained by defining a kernel Kphenotype between dis-
eases that measures their phenotypic similarity, and
plugging it into the general pairwise kernel (3). Here
we propose to use the phenotypic similarity measure
for diseases based on text mining proposed by [36].
Since this measure is derived as a correlation mea-
sure, the matrix whose entries contain the pairwise
similarity measures is eligible for kernel learning.
We call the resulting gene prioritization method
ProDiGe3 below.
￿ The phenotype+Dirac kernel. Finally, we propose a
slight variant to the phenotype kernel by adding to it
the Dirac kernel:
KP+D(D,D )=
Kphenotype(D,D )+KDirac(D,D ).
(6)
The motivation for this kernel is that, since the
description of disease phenotypes we use to build
Kphenotype is incomplete and does not fully character-
ize the disease, it may occur that two different dis-
eases, with different disease genes, have similar or
even identical phenotypic description. In this case,
the addition of the Dirac kernel in (6) allows to still
distinguish different diseases, and give more impor-
tance to the genes associated to the disease of inter-
est than to the genes associated to different diseases
with similar phenotypes. We call ProDiGe4 the
resulting gene prioritization method.
In summary, each of the four kernels for diseases pre-
sented above can be plugged into (3) to define a kernel
f o rd i s e a s e - g e n ep a i r s .T h e n ,t h eP Ul e a r n i n gs t r a t e g y
presented in the context of a single disease can be
applied to learn a scoring function over D × G . Finally,
the ranking of candidate genes in Ui for a particular dis-
ease Di is obtained by decreasing score s(Di, G)f o rG Î
Ui. We thus obtain four variants summarized in Table 6.
When heterogeneous sources of information for genes
are available, the two strategies proposed in the case of
a single disease can be easily combined with each of the
four ProDiGe variants, since each particular gene kernel
translates into a particular disease-gene kernel through
(3). In the experiments below, we only implement the
MKL approach for ProDiGe1 to compare it to the mean
kernel strategy. For other variants of ProDiGe, we
restrict ourselves to the simplest strategy where the dif-
ferent information sources are fused through kernel
averaging.
Experimental setting
We assess the performance of various gene prioritization
methods by leave-one-out cross-validation (LOOCV) on
the dataset of known disease-gene association extracted
from the OMIM database. Given the list of all disease-
gene associations (Dd(i), Gg(i))i = 1,...,T in OMIM, we
remove each pair (Dd(i), Gg(i)) in turn from the training
set, train the scoring function from the T - 1 remaining
positive pairs, rank all genes G not associated to Dd(i)i n
the training set by decreasing score s(Dd(i), G), and
check how well Gg(i) is ranked in the list. Note that in
this setting, we implicitly assume that the candidate
genes for a disease are all genes not known to be asso-
ciated to the disease, i.e., Ui = G\Pi . In the LOOCV set-
ting, each time a pair (Dd(i), Gg(i)) is removed from the
training set, the ranking is then performed on Ud(i) ∪
{Gg(i)}. We monitor the success of the prioritization by
the rank of Gg(i) among candidate genes in Ud(i). Since
we are doing a LOOCV procedure, the rank of the left-
out sample is directly related to the classical area under
the Receiver Operating Characteristics curve (AUC), via
the formula rank =( | U|+1) × (1- AUC). Therefore, an
easy way to visualize the performance of a gene prioriti-
zation method is to plot the empirical cumulative
Table 6 Summary of ProDiGe variants
Name Disease kernel Sharing of disease gene information across diseases
Prodige1 KDirac No sharing.
Prodige2 1 + KDirac Uniform sharing.
Prodige3 Kphenotype Sharing weighted by phenotypic similarity.
Prodige4 KDirac + Kphenotype Sharing weighted by phenotypic similarity and disease identity.
We propose four variants, which differ in the way they share information across diseases, as summarized in the third column of the table. The second column
shows the kernel for diseases used by each variant to achieve the sharing of information.
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associations in the training set in the LOOCV proce-
dure. For a given value of the rank k, the CDF at level k
is defined as the proportion of associations Dd(i), Gg(i)
for which gene Gg(i)r a n k e da m o n gt h et o pk in the
prioritization list for disease Dd(i), which can also be
called the recall as a function of k.
Other gene prioritization methods
We compare ProDiGe to two state-of-the-art gene
prioritization methods. First we consider the 1-SVM L2-
MKL from [10], which extends and outperforms the
Endeavour method [10], and which we denote
MKL1class below. This method performs one-class
SVM [37] while optimizing the linear combination of
gene kernels with a MKL approach in the same time.
We downloaded a Matlab implementation of all func-
tions from the supplementary information website of
[ 1 0 ] .W eu s e da si n p u tt h es a m e9k e r n e l sa sf o rP r o -
DiGe, and we set the regularization parameter of the
algorithm ν =0 . 5 ,a sd o n eb y[ 1 0 ] .S e c o n d ,w ec o m p a r e
ProDiGe to the PRINCE method introduced by [14],
which is designed to share information across the dis-
eases. Prior information consists in gene labels that are
a function of their relatedness to the query disease.
They are higher for genes known to be directly related
to the query disease, high but at a lesser extent for
genes related to a disease which is very similar to the
query, smaller for genes related to a disease that bears
little similarity to the query and zero for genes not
related to any disease. PRINCE propagates these labels
on a PPI network and produces gene scores that vary
smoothly over the network. We used the same PPI net-
work for PRINCE as the one used by ProDiGe.
Data
The first type of data required by ProDiGe is the
description of the set G of human genes. We borrowed
the dataset of [7], based on Ensembl v39 and which
contains multiple data sources. We removed genes
whose ID had a “retired” status in Ensembl v59, leaving
us with 19540 genes. These genes are described by
microarray expression profiles from [38] and [39] (MA1,
MA2), expressed sequence tag data (EST), functional
annotation (GO), pathway membership (KEGG), pro-
tein-protein interactions from the Human Protein Refer-
ence Database (PPI), transcriptional motifs (MOTIF),
protein domain activity from InterPro (IPR) and litera-
ture data (TEXT). For PPI data which consists in a
graph of interactions, a diffusion kernel with parameter
1 was computed to obtain a kernel for genes [40]. All
other data sources provide a vectorial representation of
a gene. The inner product between these vectors defines
the kernel we create from each data source. All kernels
are normalized to unit diagonal to ensure that kernel
values are comparable between different data sources,
using the formula:
˜ K(G,G ) ←
K(G,G )

K(G,G) × K(G ,G )
. (7)
Second, to define the phenotype kernel between dis-
eases we borrow the phenotypic similarity measure of
[36]. The measure they propose is obtained by auto-
matic text mining. A disease is described in the OMIM
database by a text record [25]. In particular, its descrip-
tion contains terms from the Mesh (medical subject
headings) vocabulary [36]. assess the similarity between
two diseases by comparing the Mesh terms content of
their respective record in OMIM. We downloaded the
similarity matrix for 5080 diseases from the MimMiner
webpage.
Finally, we collected disease-gene associations from
the OMIM database [25], downloaded on August 8th,
2010. We obtained 3222 disease-gene associations invol-
ving 2606 disorders and 2182 genes.
Acknowledgements
We are grateful to Léon-Charles Tranchevent, Shi Yu and Yves Moreau for
providing the gene datasets, and to Roded Sharan and Oded Magger for
making their Matlab implementation of PRINCE available to us. This work
was supported by ANR grants ANR-07-BLAN-0311-03 and ANR-09-BLAN-
0051-04.
Author details
1Centre for Computational Biology, Mines ParisTech, Fontainebleau,F-77300
France.
2Institut Curie, Paris, F-75248 France.
3U900, INSERM, Paris, F-75248
France.
4CREST, INSEE, Malakoff, F-92240 France.
Authors’ contributions
FM and JPV designed the study, analyzed the results and wrote the
manuscript. FM implemented the method and performed all experiments.
Both authors read and approved the final manuscript.
Received: 23 June 2011 Accepted: 6 October 2011
Published: 6 October 2011
References
1. Giallourakis C, Henson C, Reich M, Xie X, Mootha VK: Disease gene
discovery through integrative genomics. Annu Rev Genomics Hum Genet
2005, 6:381-406.
2. Perez-Iratxeta C, Bork P, Andrade MA: Association of genes to genetically
inherited diseases using data mining. Nat Genet 2002, 31(3):316-319.
3. Turner FS, Clutterbuck DR, Semple CAM: POCUS: mining genomic
sequence annotation to predict disease genes. Genome Biol 2003, 4(11):
R75.
4. Tiffin N, Kelso JF, Powell AR, Pan H, Bajic VB, Hide WA: Integration of text-
and data-mining using ontologies successfully selects disease gene
candidates. Nucleic Acids Res 2005, 33(5):1544-1552.
5. Freudenberg J, Propping P: A similarity-based method for genome-wide
prediction of disease-relevant human genes. Bioinformatics 2002,
18(Suppl 2):S110-S115.
6. Aerts S, Lambrechts D, Maity S, Van Loo P, Coessens B, De Smet F,
Tranchevent LC, De Moor B, Marynen P, Hassan B, Carmeliet P, Moreau Y:
Gene prioritization through genomic data fusion. Nat Biotechnol 2006,
24(5):537-544.
Mordelet and Vert BMC Bioinformatics 2011, 12:389
http://www.biomedcentral.com/1471-2105/12/389
Page 14 of 157. De Bie T, Tranchevent LC, van Oeffelen LMM, Moreau Y: Kernel-based data
fusion for gene prioritization. Bioinformatics 2007, 23(13):i125-i132.
8. Linghu B, Snitkin E, Hu Z, Xia Y, Delisi C: Genome-wide prioritization of
disease genes and identification of disease-disease associations from an
integrated human functional linkage network. Genome Biol 2009, 10(9):
R91.
9. Hwang T, Kuang R: A Heterogeneous Label Propagation Algorithm for
Disease Gene Discovery. Proceedings of the SIAM International Conference
on Data Mining, SDM 2010, April 29 - May 1, 2010, Columbus, Ohio, USA
2010, 583-594.
10. Yu S, Falck T, Daemen A, Tranchevent LC, Suykens Y, De Moor B, Moreau Y:
L2-norm multiple kernel learning and its application to biomedical data
fusion. BMC Bioinformatics 2010, 11:309.
11. Ala U, Piro R, Grassi E, Damasco C, Silengo L, Oti M, Provero P, Di Cunto F:
Prediction of human disease genes by human-mouse conserved
coexpression analysis. PLoS Comput Biol 2008, 4(3):e1000043.
12. Wu X, Jiang R, Zhang M, Li S: Network-based global inference of human
disease genes. Mol Syst Biol 2008, 4:189.
13. Köhler S, Bauer S, Horn D, Robinson P: Walking the interactome for
prioritization of candidate disease genes. Am J Hum Genet 2008,
82(4):949-958.
14. Vanunu O, Magger O, Ruppin E, Shlomi T, Sharan R: Associating genes and
protein complexes with disease via network propagation. PLoS Comput
Biol 2010, 6:e1000641.
15. Tranchevent LC, Capdevila FB, Nitsch D, De Moor B, De Causmaecker P,
Moreau Y: A guide to web tools to prioritize candidate genes. Brief
Bioinform 2011, 11(1):22-32.
16. Liu B, Lee WS, Yu PS, Li X: Partially Supervised Classification of Text
Documents. ICML ‘02: Proceedings of the Nineteenth International Conference
on Machine Learning San Francisco, CA, USA: Morgan Kaufmann Publishers
Inc; 2002, 387-394[http://citeseerx.ist.psu.edu/viewdoc/download?
doi=10.1.1.78.6998&rep=rep1&type=pdf].
17. Denis F, Gilleron R, Letouzey F: Learning from positive and unlabeled
examples. Theor Comput Sci 2005, 348:70-83.
18. Mordelet F, Vert JP: A bagging SVM to learn from positive and unlabeled
examples. Tech Rep 00523336, HAL 2010 [http://hal.archives-ouvertes.fr/hal-
00523336].
19. Evgeniou T, Micchelli C, Pontil M: Learning multiple tasks with kernel
methods. J Mach Learn Res 2005, 6:615-637[http://jmlr.csail.mit.edu/papers/
volume6/evgeniou05a].
20. Jacob L, Vert JP: Efficient peptide-MHC-I binding prediction for alleles
with few known binders. Bioinformatics 2008, 24(3):358-366.
21. Jacob L, Vert JP: Protein-ligand interaction prediction: an improved
chemogenomics approach. Bioinformatics 2008, 24(19):2149-2156.
22. Pavlidis P, Weston J, Cai J, Noble W: Learning Gene Functional
Classifications from Multiple Data Types. J Comput Biol 2002, 9(2):401-411.
23. Schölkopf B, Tsuda K, Vert JP: Kernel Methods in Computational Biology.
The MIT Press, Cambridge, Massachussetts: MIT Press; 2004.
24. Lanckriet GRG, De Bie T, Cristianini N, Jordan MI, Noble WS: A statistical
framework for genomic data fusion. Bioinformatics 2004, 20(16):2626-2635.
25. McKusick V: Mendelian Inheritance in Man and its online version, OMIM.
Am J Hum Genet 2007, 80(4):588-604.
26. Brancotte B, Biton A, Bernard-Pierrot I, Radvanyi F, Reyal F, Cohen-
Boulakia S: Gene List significance at-a-glance with GeneValorization.
Bioinformatics 2011, 27(8):1187-1189.
27. Calvo B, López-Bigas N, Furney S, Larrañaga P, Lozano J: A partially
supervised classification approach to dominant and recessive human
disease gene prediction. Comput Methods Programs Biomed 2007,
85(3):229-237.
28. Schölkopf B, Smola AJ: Learning with Kernels: Support Vector Machines,
Regularization, Optimization, and Beyond Cambridge, MA: MIT Press; 2002.
29. Chang CC, Lin CJ: LIBSVM: a library for support vector machines 2001 [http://
www.csie.ntu.edu.tw/~cjlin/libsvm].
30. Yamanishi Y, Vert JP, Kanehisa M: Protein network inference from multiple
genomic data: a supervised approach. Bioinformatics 2004, 20:i363-i370.
31. Bleakley K, Biau G, Vert JP: Supervised reconstruction of biological
networks with local models. Bioinformatics 2007, 23(13):i57-i65.
32. Lanckriet G, Cristianini N, Bartlett P, El Ghaoui L, Jordan M: Learning the
kernel matrix with semidefinite programming. J Mach Learn Res 2004,
5:27-72[http://www.jmlr.org/papers/v5/lanckriet04a.html].
33. López-Bigas N, Ouzounis CA: Genome-wide identification of genes likely
to be involved in human genetic disease. Nucleic Acids Res 2004,
32(10):3108-3114.
34. Adie EA, Adams RR, Evans KL, Porteous DJ, Pickard BS: Speeding disease
gene discovery by sequence based candidate prioritization. BMC
Bioinformatics 2005, 6:55.
35. Lage K, Karlberg E, Størling Z, Olason P, Pedersen A, Rigina O, Hinsby A,
Tümer Z, Pociot F, Tommerup N, Moreau Y, Brunak S: A human phenome-
interactome network of protein complexes implicated in genetic
disorders. Nat Biotechnol 2007, 25(3):309-316.
36. van Driel M, Bruggeman J, Vriend G, Brunner H, Leunissen J: A text-mining
analysis of the human phenome. Eur J Hum Genet 2006, 14(5):535-542.
37. Schölkopf B, Platt JC, Shawe-Taylor J, Smola AJ, Williamson RC: Estimating
the support of a high-himensional distributions. Neural Comput 2001,
13:1443-1471.
38. Son C, Bilke S, Davis S, Greer B, Wei J, Whiteford C, Chen QR, Cenacchi N,
Khan J: Database of mRNA gene expression profiles of multiple human
organs. Genome Res 2005, 15(3):443-450.
39. Su A, Cooke M, Ching K, Hakak Y, Walker J, Wiltshire T, Orth A, Vega R,
Sapinoso L, Moqrich A, Patapoutian A, Hampton G, Schultz P, Hogenesch J:
Large-scale analysis of the human and mouse transcriptomes. Proc Natl
Acad Sci USA 2002, 99(7):4465-4470.
40. Kondor RI, Lafferty J: Diffusion kernels on graphs and other discrete
input. Proceedings of the Nineteenth International Conference on Machine
Learning San Francisco, CA, USA: Morgan Kaufmann Publishers Inc; 2002,
315-322.
doi:10.1186/1471-2105-12-389
Cite this article as: Mordelet and Vert: ProDiGe: Prioritization Of Disease
Genes with multitask machine learning from positive and unlabeled
examples. BMC Bioinformatics 2011 12:389.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mordelet and Vert BMC Bioinformatics 2011, 12:389
http://www.biomedcentral.com/1471-2105/12/389
Page 15 of 15